Superior treatment response and in-field tumor control in epidermal growth factor receptor-mutant genotype of stage III nonsquamous non-small cell lung cancer undergoing definitive concurrent chemoradiotherapy

We conducted comparative outcome analysis to evaluate the differential radioresponse and survival outcomes in epidermal growth factor receptor (EGFR)-mutant and wild-type nonsquamous non-small cell lung cancer (NSCLC) undergoing definitive chemoradiotherapy. With more favorable metabolic activity, the EGFR-mutant group showed significantly better post-chemoradiation response and superior tumor control inside the radiation field. Our results underline the need of precise therapeutic strategy based on the EGFR mutational status.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iQvsQi
via IFTTT